Literature DB >> 19052557

Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy.

D Bruennert, A Czibere, I Bruns, R Kronenwett, N Gattermann, R Haas, F Neumann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19052557     DOI： 10.1038/leu.2008.337

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  hsa-mir183/EGR1-mediated regulation of E2F1 is required for CML stem/progenitor cell survival.

Authors:  Francesca Pellicano; Laura Park; Lisa E M Hopcroft; Mansi M Shah; Lorna Jackson; Mary T Scott; Cassie J Clarke; Amy Sinclair; Sheela A Abraham; Alan Hair; G Vignir Helgason; Mark Aspinall-O'Dea; Ravi Bhatia; Gustavo Leone; Kamil R Kranc; Anthony D Whetton; Tessa L Holyoake
Journal:  Blood       Date:  2018-02-05       Impact factor: 22.113

2.  Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia.

Authors:  Anna Chorzalska; Javier Flores Kim; Karim Roder; Alexander Tepper; Nagib Ahsan; R Shyama Prasad Rao; Adam J Olszewski; Xiaoqing Yu; Dmitry Terentyev; John Morgan; Diana O Treaba; Ting C Zhao; Olin Liang; Philip A Gruppuso; Patrycja M Dubielecka
Journal:  Stem Cells Dev       Date:  2017-02-27       Impact factor: 3.272

3.  Cks1 is a critical regulator of hematopoietic stem cell quiescence and cycling, operating upstream of Cdk inhibitors.

Authors:  V Tomiatti; R Istvánffy; E Pietschmann; S Kratzat; A Hoellein; L Quintanilla-Fend; N von Bubnoff; C Peschel; R A J Oostendorp; U Keller
Journal:  Oncogene       Date:  2014-11-24       Impact factor: 9.867

4.  Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia.

Authors:  Stefania Trino; Luciana De Luca; Vittorio Simeon; Ilaria Laurenzana; Annalisa Morano; Antonella Caivano; Francesco La Rocca; Giuseppe Pietrantuono; Gabriella Bianchino; Vitina Grieco; Elisabetta Signorino; Alberto Fragasso; Maria Teresa Bochicchio; Claudia Venturi; Gianantonio Rosti; Giovanni Martinelli; Luigi Del Vecchio; Daniela Cilloni; Pellegrino Musto
Journal:  Tumour Biol       Date:  2015-07-21

5.  A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

Authors:  Leyuan Ma; Yi Shan; Robert Bai; Liting Xue; Christopher A Eide; Jianhong Ou; Lihua J Zhu; Lloyd Hutchinson; Jan Cerny; Hanna Jean Khoury; Zhi Sheng; Brian J Druker; Shaoguang Li; Michael R Green
Journal:  Sci Transl Med       Date:  2014-09-03       Impact factor: 17.956

6.  BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.

Authors:  Christian Hurtz; Katerina Hatzi; Leandro Cerchietti; Melanie Braig; Eugene Park; Yong-mi Kim; Sebastian Herzog; Parham Ramezani-Rad; Hassan Jumaa; Martin C Müller; Wolf-Karsten Hofmann; Andreas Hochhaus; B Hilda Ye; Anupriya Agarwal; Brian J Druker; Neil P Shah; Ari M Melnick; Markus Müschen
Journal:  J Exp Med       Date:  2011-09-12       Impact factor: 14.307

7.  Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.

Authors:  Abdullah Aljedai; Anne-Marie Buckle; Prashant Hiwarkar; Farhatullah Syed
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

8.  Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells.

Authors:  Bin Zhang; Su Chu; Puneet Agarwal; Victoria L Campbell; Lisa Hopcroft; Heather G Jørgensen; Allen Lin; Karl Gaal; Tessa L Holyoake; Ravi Bhatia
Journal:  Blood       Date:  2016-09-12       Impact factor: 22.113

9.  The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.

Authors:  Francesca Pellicano; Mary T Scott; G Vignir Helgason; Lisa E M Hopcroft; Elaine K Allan; Mark Aspinall-O'Dea; Mhairi Copland; Andrew Pierce; Brian J P Huntly; Anthony D Whetton; Tessa L Holyoake
Journal:  Stem Cells       Date:  2014-09       Impact factor: 6.277

10.  Shift in energy metabolism caused by glucocorticoids enhances the effect of cytotoxic anti-cancer drugs against acute lymphoblastic leukemia cells.

Authors:  Shigeki Aoki; Michie Morita; Takuya Hirao; Masashi Yamaguchi; Reika Shiratori; Megumi Kikuya; Hiroji Chibana; Kousei Ito
Journal:  Oncotarget       Date:  2017-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.